| INTRODUCTION
Despite major advances in the prevention and treatment of atherothrombosis, coronary artery disease (CAD) is the primary cause of mortality worldwide, continues to be a major burden on public health, 1, 2 and is expected to remain the world's leading cause of morbidity and mortality in 2020. 3 The number of patients with CAD is likely to rise as life expectancy increases, as the prevalences of diabetes mellitus (DM) and obesity increase, and due to the improved survival of patients presenting with an acute coronary syndrome. 4 The clinical characteristics, cardiovascular (CV) risk factors, treatment, and outcomes of patients with CAD have changed markedly over the years. Most of the existing data regarding the epidemiology of CAD are relatively old, often focus on 1 manifestation of disease (eg, stable angina) 5 or pertain to acute coronary syndromes, 6 and are often restricted to a single country or a specific geographic region, particularly North America or Western Europe. [7] [8] [9] Thus, there is a need for robust contemporary data in stable CAD representing >1 region and addressing more than symptomatic angina. Moreover, despite the importance of heart rate (HR) in the prognosis of stable CAD, [10] [11] [12] [13] [14] HR is not a routine component of CV risk assessment, nor a tool to decide whether treatment is indicated, and most datasets have not collected detailed information on HR in stable CAD.
Large datasets are available from randomized trials in stable CAD. However, although these are the gold standard to evaluate new therapies, 15 they are generally performed in highly selected populations that often do not reflect patients encountered in daily practice in terms of their clinical characteristics, comorbidities, socioeconomic status, management, and outcomes. 16 Large prospective registries often provide a more realistic description of the patients' actual characteristics, management, and outcomes, provided their recruitment is unbiased and the sample size is sufficiently large. 17, 18 The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) was initiated to improve knowledge about the current management and outcomes of patients with stable CAD, to assess prognosis, and to subsequently design interventions to improve evaluation and treatment of these patients.
2 | METHODS
| Objectives
The first objective was to describe contemporary patients with stable CAD in terms of their demographic characteristics, clinical profile, management, and outcomes, with a global geographic reach, encompassing patients from high-, middle-, and low-income regions. The second objective was to identify gaps between evidence-based recommendations and current management. The third objective was to characterize the clinical determinants of long-term prognosis in this population.
| Study design
CLARIFY is an ongoing international, prospective, observational, lon- (Figure 1 ).
FIGURE 1
Worldwide distribution of study participants (n = 32703).
Importantly, no patients were enrolled in the United States, due to a lack of sponsor support. 
| Site selection
To ensure that the enrolled population of outpatients with stable CAD was representative of the population of each country, sites
were identified based on a predefined selection of physicians including cardiologists, general practitioners, internists, and hospital-based physicians. In each country, selection of physicians was made by national coordinators using the best available epidemiological data reflecting the burden of CAD in that country, to provide a representative distribution of physicians across regions and location types (ie, urban, suburban, and rural areas 
| Data collection and evaluation
Data were collected anonymously using electronic standardized inter- 
| Outcomes
The main outcomes collected during the 5-year follow-up included mortality and CV morbidity data. Deaths were categorized into fatal MI, fatal stroke and other CV death (including sudden death), non-CV death (death that was not definitely CV), and unknown cause. Events To ensure data quality, every year, 1% of the centers were randomly selected to perform on-site audits. In these selected centers, 100% of the data for all patients were checked for source documentation and accuracy. Data quality control was done at face-to-face quality-control visits and involved review of source documents supporting the adequacy and accuracy of data collected on the casereport forms.
| Statistical analysis
CLARIFY is an observational registry, and the size of the population was not based on a planned treatment comparison. The number of patients to be included was computed based on the aim to build a robust risk model at the completion of follow-up and depended on the CV event rate, number of subjects lost to follow-up, and study duration. Based on data from the literature, the annual rates of CV death and of major adverse CV events were expected to be approximately 2% and 4.5%, respectively. CLARIFY had to screen ≥31 
| RESULTS
A total of 33 032 patients were enrolled in the CLARIFY Registry. Of these, 329 withdrew their consent or did not meet the inclusion criteria. The baseline study population was therefore 32 703 patients ( Figure 2 ).
Baseline demographics are detailed in and Caucasian (64.6%). The median body mass index was 27.3, indicating that the majority of subjects were overweight or obese. Likewise, a majority of patients were either current or former smokers, dyslipidemic, and treated for hypertension. The majority of the patients did not work, and most reported only light physical activity.
Overall, based on the 4 main (not mutually exclusive) inclusion criteria, 57.7% of patients were enrolled on the basis of a medical At the time of enrollment, most patients were asymptomatic, without symptoms of angina or HF. Mean BP readings were within the normal range, as were the values for creatinine and fasting blood glucose ( Table 2 ). Mean resting HR was 68.2 AE 10.6 bpm when measured by pulse (available in 32 673 patients) and 67.1 AE 11.4 bpm when measured by ECG (available in 24 438 patients), and most patients were in sinus rhythm. Among the 22 519 patients in whom a measurement was available, mean LVEF was 56.1% AE 11.1%. Among patients with results of coronary angiography within the past 12 months, almost all patients had ≥1 significant coronary stenosis:
58.3% had a significant stenosis localized in the left anterior descending artery, 36.1% in the left circumflex artery, 43.5% in the right coronary artery, and 8.7% in the left main stem. Of note, 3.2% of patients with angiographic data had no stenosis >50%.
At baseline, the CLARIFY population had high rates of use of evidence-based drugs for prevention in CAD (Table 3) . Most patients were receiving aspirin (ASA; 87.8%) and lipid-lowering drugs (92.3%).
Rates of β-blocker, angiotensin-converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker therapies were 75.3%, 51.7%, and 26.5%, respectively. Three-quarters of patients received either full (39.2%) or partial (37.7%) reimbursement for their CV agents.
Overall, the clinical characteristics of the 4 groups were similar, although patients in the group with symptomatic angina were slightly older, with a higher prevalence of DM, treated hypertension, and dyslipidemia, and less physical activity (Table 1) . Patients with angina also more frequently had a history of atrial fibrillation/flutter, peripheral artery disease, and asthma/chronic obstructive pulmonary disease (Table 2) . Given the size of the cohort, these modest differences were significant. There were, however, notable differences in management between groups: patients with a history of MI were more likely to receive ASA, β-blockers, and ACEIs and less likely to receive calcium antagonists than the other groups (Table 3) . Also, the use of some non-CV drug classes was substantial (eg, proton pump inhibitors Data are presented as n (%), mean AE SD, or median (IQR).
a Inclusion criteria are not mutually exclusive; some patients may be included in >1 group.
Hg were each associated with CV events, including mortality, supporting the existence of a J-curve phenomenon and suggesting that caution should be taken with the use of BP-lowering treatment in patients with hypertension and CAD. 25 Despite high rates of use of β-blockers, patients with stable CAD often have resting HR ≥70 bpm, which has been associated with an overall worse health status, more frequent angina, and ischemia. 26 Sex-and age-related differences have also been identified. Women were more likely to have angina but less likely to have undergone revascularization procedures; and patients ≥75 years' old were less often treated with β-blockers, ASA, and ACEIs than were patients ≤65 years' old. 27 However, after 1-year follow-up, there was no clear difference in age-adjusted outcomes between men and women with stable CAD. 28 Compared with normal renal function, chronic renal insufficiency was associated with a lower use of evidence-based medications for secondary prevention, including antiplatelet drugs, statins, β-blockers, and ACEIs. 29 In patients with atrial fibrillation within CLARIFY, anticoagulants were markedly underused, whereas antiplatelet therapy was still widely used, both of which are at odds with contemporary international guidelines. [30] [31] [32] Finally, in patients who underwent noninvasive testing, the presence of anginal symptoms (with or without ischemia) appeared to be associated with a higher risk of adverse CV outcomes than ischemia per se. 33 An additional finding of that analysis was that approximately 70% of events occurred in patients with no evidence of myocardial ischemia on noninvasive testing, indicating that focusing the management of stable CAD solely on the prevention or treatment of ischemia does not address the risks that these patients face. 33 A particular focus will be given to these populations (ie, with or without anginal symptoms and with or without proven ischemia on noninvasive testing) to try to explain the differences in CV outcomes.
Despite the size and scope of CLARIFY, the registry is not without important limitations. First, as with any observational database, it is difficult to rule out selection biases and confounding. We attempted to improve the representativeness of the cohort: minimizing the risk of selection bias by drastically limiting the enrollment period and attempting to balance representation of each country by targeting a fixed proportion of patients in relation to each country's population. Second, although patients were enrolled in North and Central America, there was no enrollment in the United States. Third, there was not 100% source data monitoring, but audits were performed in randomly selected sites and data were reviewed and queried remotely. Finally, events were collected as reported by investigators and there was no central adjudication, although a set of short definitions was included in the case-report forms to assist investigators in defining and identifying clinical characteristics and outcomes.
| CONCLUSION
The CLARIFY Registry will provide a large database of contemporary international data regarding the characteristics, management, and outcomes of patients with stable CAD.
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